45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptorß agonists.
Eli Lilly
Identification of the first potent, selective and bioavailable PPARa antagonist.
Inception Sciences
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptorß agonist in clinical trials for the treatment of dyslipidemia.
Madrigal Pharmaceuticals
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptorß agonists.
Sanwa Kagaku Kenkyusho
Development of novel Vitamin D Receptor-Coactivator Inhibitors.
University Of Wisconsin-Milwaukee
Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction.
St. Jude Children'S Research Hospital
Identification of Potent and Selective Diphenylpropanamide ROR? Inhibitors.
New York University School Of Medicine
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptorß (TRß) selective agonists.
Kissei Pharmaceutical
QSAR study of selective ligands for the thyroid hormone receptor beta.
University Of Insubria
Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.
Zydus Research Centre
Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.
Institut Pasteur Korea
Discovery of novel indane derivatives as liver-selective thyroid hormone receptorß (TRß) agonists for the treatment of dyslipidemia.
Kissei Pharmaceutical
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
University Of California San Francisco
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.
Abbott Laboratories
Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.
St. Jude Children'S Hospital
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
Metabasis Therapeutics
Design and synthesis of novel 3-hydroxy-cyclobut-3-ene-1,2-dione derivatives as thyroid hormone receptor beta (TR-beta) selective ligands.
Zydus Research Centre
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
Metabasis Therapeutics
Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta.
Karo Bio
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
Pharmaceutical Research Institute
Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
Eli Lilly
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
Pfizer
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
University Of California
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
Karo Bio
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPAR?.
Goethe-University Frankfurt
Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.
Inception Sciences
Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-? agonists (SERBAs).
Marquette University
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Purdue Pharma Discovery Research
WAY-855 (3-amino-tricyclo[2.2.1.02.6]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake.
Wyeth Research